Takara Bio Inc.
Division of Takara Holdings Inc.
Latest From Takara Bio Inc.
2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will this play out and what else can we expect in this key market over the next year?
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
- Gene Therapy, Cell Therapy
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- Takara Biomedical
- Pacific Rim
- Parent & Subsidiaries
- Takara Holdings Inc.
- Senior Management
- Koichi Nakao, Pres. & CEO
- Contact Info
Takara Bio Inc.
Phone: (81) 77 543 7200
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.